For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 1,834,506 | |||
| General and administrative | 6,257,477 | |||
| Total operating expenses | 8,091,983 | |||
| Operating loss | -8,091,983 | |||
| Interest income | 125,445 | |||
| Net loss | -7,966,538 | |||
| Basic EPS | -5.32 | |||
| Diluted EPS | -5.32 | |||
| Basic Average Shares | 1,498,793 | |||
| Diluted Average Shares | 1,498,793 | |||
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)